Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Has Japan Launched A $420m Fund For Bioventures?

Application For VCs Opened In Ecosystem Bid

Executive Summary

A new national project to support bioventures and the venture capital funds investing in them has started in Japan. The strategic aim of the JPY50bn initiative is to enhance the speed of development and trials of new drugs and vaccines for infectious diseases, the lack of which became obvious since the breakout of COVID-19. 

You may also be interested in...



Japan Kicks Off $366m Bioventure Support Program

A new state-supported scheme is to provide funding for R&D programs at Japanese bioventures, with up to JPY10bn available for each project. Eight selected VCs will fund one-third of the total, with the government to provide the rest.

Japan Lists Eight Infectious Diseases For Focused Vaccine Development

The list including eight types of diseases such as flu and coronavirus infection, smallpox will be sent to SCARDA to determine which domestic vaccine development projects by pharmaceutical firms are to be funded. Some participants at the Ministry of Health, Labour and Welfare’s discussion insisted on continuous monitoring.

SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?

Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. 

 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel